Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Inosine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Inosine. Displaying page 1 of 1.
    EudraCT Number: 2012-000796-16 Sponsor Protocol Number: GAMr-30 Start Date*: 2012-07-09
    Sponsor Name:OCTAPHARMA AG
    Full Title: PROSPECTIVE, OPEN-LABEL, NON-CONTROLLED, MULTICENTER, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCTAGAM 10% IN PRIMARY IMMUNE THROMBOCYTOPENIA
    Medical condition: Primary Immune Thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10023095 ITP LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004295-22 Sponsor Protocol Number: NL59645.098.16 Start Date*: 2017-04-10
    Sponsor Name:Hagaziekenhuis
    Full Title: Treatment of thromBocytopenia with EltRombopag or Intravenous Immune Globulin (IVIG) Before and DurING Invasive Procedures in Patients with Immune ThrombocytoPenia.
    Medical condition: Immune thrombocytopenia patients with low platelets and in need of surgery.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004851 10023095 ITP LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001597-33 Sponsor Protocol Number: 20081203 Start Date*: 2009-06-18
    Sponsor Name:University Medical Center Utrecht
    Full Title: Development of chronic disease in newly diagnosed Idiopathic Thrombocytopenic Purpura of Childhood. A randomized controlled study on the influence of treatment with intravenous gammaglobulin on the...
    Medical condition: Acute Idiopathic Thrombocytopenic Purpura (ITP) in children
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10023095 ITP LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001354-29 Sponsor Protocol Number: I10E-0719 Start Date*: 2011-10-12
    Sponsor Name:LFB BIOTECHNOLOGIES
    Full Title: An open-label, multicentre efficacy and safety study of I10E in patients with primary Immune ThrombocytoPenia (ITP)
    Medical condition: ITP diagnosis being defined by ASH-2011 and BCSH 2010 criteria adopting the new consensus terminology proposed by an international working group (Rodeghiero et al, 2009)
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004851 10023095 ITP LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) IT (Completed) ES (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2009-014589-24 Sponsor Protocol Number: NGAM-02 Start Date*: 2011-09-22
    Sponsor Name:Octapharma AG
    Full Title: Prospective, Open-label, Non-controlled, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NEWGAM) in Primary Immune Thrombocytopenia
    Medical condition: Primary Immune Thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10005329 - Blood and lymphatic system disorders 10023095 ITP LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) BG (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002478-11 Sponsor Protocol Number: 2.0 Start Date*: 2016-07-19
    Sponsor Name:Medical University of Vienna, Department of Internal medicine I
    Full Title: Very low doses of Rituximab for off-label treatment – a Pilot Trial
    Medical condition: Autoimmune-haemolytic Anemia Antiphospholipid Syndrome Immune-mediated Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000154058 10003825 Autoimmune hemolytic anemia LLT
    20.0 100000157088 10023095 ITP LLT
    20.0 10005329 - Blood and lymphatic system disorders 10002817 Antiphospholipid syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004235-36 Sponsor Protocol Number: EWO-ISO-2017/2 Start Date*: 2018-09-27
    Sponsor Name:Ewopharma AG
    Full Title: A phase 4, randomized, open label multi-centre clinical study to evaluate efficacy of Isoprinosine® in female subjects with low-grade cervical dysplasia caused by HrHPV.
    Medical condition: Low-grade cervical dysplasia caused by HrHPV
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2013-003303-18 Sponsor Protocol Number: rl.01.2013 Start Date*: Information not available in EudraCT
    Sponsor Name:Gedeon Richter Polska Sp. z o. o.
    Full Title: Clinical phase IV study assessing the efficacy and safety of the medicinal product Groprinosin in treatment of recurrent airway inflammation in children with impaired cellular immunity and diagnose...
    Medical condition: Recurrent airway inflammation in children with impaired cellular immunity.
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-014997-16 Sponsor Protocol Number: MPASNP1 Start Date*: 2010-04-08
    Sponsor Name:Medizinische Universität Wien, Abteilung für Nephrologie und Dialyse
    Full Title: Identification of patients with high probability of not or poorly responding to therapy with mycophenolic acid pro-drugs.
    Medical condition: Patients with a de novo kidney transplantation
    Disease: Version SOC Term Classification Code Term Level
    12.0 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004810-41 Sponsor Protocol Number: MV28073 Start Date*: 2012-04-18
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: An international, multicenter, open-label study evaluating sustained virological response and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in...
    Medical condition: Genotype 1 CHC virus infection
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) ES (Completed) PL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001863-11 Sponsor Protocol Number: EWO-ISO-2014/1 Start Date*: 2014-09-24
    Sponsor Name:Ewopharma AG.
    Full Title: A Phase 4, Randomised, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate Efficacy of Isoprinosine® in Comparison With Placebo in Subjects With Confirmed Acute Respiratory Viral Infect...
    Medical condition: Acute Respiratory Viral Infections due to influenza A or B virus, RSV, adenovirus, or parainfluenza virus 1 or 3
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10022005 Influenza viral infections HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-001096-39 Sponsor Protocol Number: MV25600 Start Date*: 2012-07-10
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: An International, Multi-Center Study Evaluating the Correlation of IL28B Genotypes with Chronic Hepatitis C Disease Characteristics and Patient Demographics
    Medical condition: Chronic hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    14.1 10022891 - Investigations 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:28:43 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA